A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Androgenetic Alopecia Clinical Trial

Official title:

An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03495817
• Other study ID #: ATI-50002-AGA-201
• Status: Completed
• Phase: Phase 2
• Start date: March 22, 2018
• Est. completion date: October 30, 2019

Study information

• Verified date: November 2020
• Source: Aclaris Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

Description:

This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: October 30, 2019
• Est. primary completion date: October 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia. Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot. Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area. Subjects must agree to maintain the same hair style and hair care regimen during the study. Exclusion Criteria: Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication. Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy. Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Androgenetic Alopecia

Intervention

Drug:
• ATI-50002
ATI-50002 Topical Solution

Locations

Country	Name	City	State
United States	Aclaris Investigational Site	Austin	Texas
United States	Aclaris Investigational Site	Denver	Colorado
United States	Aclaris Investigational Site	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Aclaris Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change From Baseline in Target Area Hair Count (TAHC)	Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.	Baseline to 26 Weeks
Secondary	Mean Change From Baseline in Target Area Hair Count (TAHC)	Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.	Baseline to 52 Weeks
Secondary	Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)	Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.	Baseline to 26 Weeks
Secondary	Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)	Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.	Baseline to 52 Weeks
Secondary	Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale	Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.	Baseline to 26 Weeks
Secondary	Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale	Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.	Baseline to 52 Weeks
Secondary	Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale	Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.	Baseline to 26 Weeks
Secondary	Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale	Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.	Baseline to 52 Weeks
Secondary	Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale	Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.; Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.	Baseline to 26 Weeks
Secondary	Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale	Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.; Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.	Baseline to 52 Weeks
Secondary	Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale	Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.; Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.; Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.; Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.; Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.	Baseline to 26 Weeks
Secondary	Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale	Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.; Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.; Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.; Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.; Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.	Baseline to 52 Weeks